Driehaus Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Driehaus Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,620	Closed	-$242K	–	593
2017 Q2	$242K	Buy	+5,620	New	+$200K	0.01%	491
2015 Q4	–	Sell	-18,397	Closed	-$258K	–	629
2015 Q3	$258K	Sell	18,397 -127,738	-87%	-$2.38M	0.01%	487
2015 Q2	$2.48M	Sell	146,135 -14,376	-9%	-$205K	0.09%	304
2015 Q1	$1.94M	Buy	+160,511	New	+$1.52M	0.07%	343
2014 Q2	–	Sell	-68,149	Closed	-$609K	–	620
2014 Q1	$609K	Buy	+68,149	New	+$628K	0.02%	441

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Driehaus Capital Management's SUPN Position: Q3 2017 in Review

Driehaus Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 5,620 shares — an estimated $242K sold.

Driehaus Capital Management first reported a position in SUPN in Q1 2014 and held it in 5 quarters. The position peaked at $2.48M in Q2 2015. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

Driehaus Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Driehaus Capital Management sold 5,620 Supernus Pharmaceuticals shares in Q3 2017, an estimated $242K.
Driehaus Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Driehaus Capital Management's Supernus Pharmaceuticals position peaked at $2.48M in Q2 2015.
275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Driehaus Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.